NVO
Novo Nordisk A/S Sponsored ADR Class B · NYSE
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website novonordisk.com
- Employees(FY) 61412
- ISIN US6701002056
Performance
+7.61%
1W
+6.34%
1M
+10.42%
3M
+31.53%
6M
+28.65%
YTD
+57.64%
1Y
Profile
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Investment Analysis Report: Novo Nordisk A/S (NVO)
Overview
Novo Nordisk A/S (NVO) is a pharmaceutical company operating in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. With a market capitalization of $423.52 billion, NVO is a significant player in the healthcare industry. In this report, we will conduct a c...
Technical Analysis of NVO 2024-05-10
Overview:
In analyzing the technical indicators for NVO over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed decis...
Recent News & Updates
- 2024-05-14 00:37
- 2024-05-13 19:52
- 2024-05-13 16:06
- 2024-05-13 15:58
Sector Update: Health Care Stocks Mixed Late Afternoon(MT Newswires)
- 2024-05-13 15:34
Remembering Quant King Jim Simons(GuruFocus.com)
- 2024-05-13 12:56
- 2024-05-13 11:49
- 2024-05-13 10:45
- 2024-05-13 09:07
- 2024-05-13 05:57
- 2024-05-12 20:47
- 2024-05-12 19:00
- 2024-05-12 13:25
- 2024-05-11 03:50
- 2024-05-10 05:44
- 2024-05-10 04:41
Novo Nordisk enters deal to develop obesity therapy(Pharmaceutical Technology)
- 2024-05-09 18:00
- 2024-05-09 10:20
- 2024-05-09 09:45
- 2024-05-09 08:41
- 2024-05-09 08:00
Making Money Off the Weight-Loss Revolution Has Even Wall Street Befuddled(The Wall Street Journal)
- 2024-05-09 07:13
- 2024-05-09 07:12
- 2024-05-09 05:27
- 2024-05-09 03:00
- 2024-05-08 21:30
- 2024-05-08 20:30
- 2024-05-08 20:26
- 2024-05-08 11:31
- 2024-05-08 09:30
Page 1 of 10
previousnext